NASDAQ:IRMD Iradimed Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Iradimed Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.30 -0.19 (-0.84 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$22.11Now: $22.30▼$22.8150-Day Range$21.00MA: $21.92▼$23.2752-Week Range$14.41Now: $22.30▼$28.43Volume62,015 shsAverage Volume48,996 shsMarket Capitalization$273.11 millionP/E Ratio51.86Dividend YieldN/ABeta1.27 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingIradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.00, Iradimed has a forecasted upside of 16.6% from its current price of $22.30.Amount of Analyst CoverageIradimed has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesIradimed has received 227 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIradimed has received 247 “underperform” votes. (Add your “underperform” vote.)Community SentimentIradimed has received 52.11% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote “Outperform” if you believe IRMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIradimed does not currently pay a dividend.Dividend GrowthIradimed does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iradimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $201,358.00 in company stock.Percentage Held by Insiders50.90% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions36.86% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Iradimed are expected to grow by 1,600.00% in the coming year, from $0.03 to $0.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iradimed is 51.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Iradimed is 51.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.04.Price to Book Value per Share RatioIradimed has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.76 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRMD Previous Symbol CUSIPN/A CIK1325618 Webwww.iradimed.com Phone407-677-8022Debt Debt-to-Equity RatioN/A Current Ratio11.44 Quick Ratio10.51Price-To-Earnings Trailing P/E Ratio51.86 Forward P/E Ratio743.33 P/E GrowthN/A Sales & Book Value Annual Sales$38.52 million Price / Sales7.09 Cash Flow$0.95 per share Price / Cash Flow23.50 Book Value$4.83 per share Price / Book4.62Profitability EPS (Most Recent Fiscal Year)$0.78 Net Income$9.63 million Net Margins14.74% Return on Equity9.57% Return on Assets8.04%Miscellaneous Employees95 Outstanding Shares12,247,000Market Cap$273.11 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $22.30 -0.19 (-0.84 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IRMD News and Ratings via Email Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter. Iradimed (NASDAQ:IRMD) Frequently Asked Questions How has Iradimed's stock been impacted by COVID-19? Iradimed's stock was trading at $22.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IRMD shares have decreased by 0.9% and is now trading at $22.30. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Iradimed? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iradimed. When is Iradimed's next earnings date? Iradimed is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Iradimed. How were Iradimed's earnings last quarter? Iradimed Corp (NASDAQ:IRMD) posted its quarterly earnings data on Thursday, July, 30th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.12. The medical equipment provider earned $6.80 million during the quarter, compared to the consensus estimate of $5.53 million. Iradimed had a return on equity of 9.57% and a net margin of 14.74%. View Iradimed's earnings history. What price target have analysts set for IRMD? 1 Wall Street analysts have issued twelve-month price objectives for Iradimed's shares. Their forecasts range from $26.00 to $26.00. On average, they expect Iradimed's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 16.6% from the stock's current price. View analysts' price targets for Iradimed. Who are some of Iradimed's key competitors? Some companies that are related to Iradimed include Cerus (CERS), GenMark Diagnostics (GNMK), OraSure Technologies (OSUR), Acutus Medical (AFIB), Orthopediatrics (KIDS), Vapotherm (VAPO), MiMedx Group (MDXG), SI-Bone (SIBN), LeMaitre Vascular (LMAT), Cryolife (CRY), Invo Bioscience (IVOB), Tactile Systems Technology (TCMD), AVITA MED LTD/S (RCEL), Orthofix Medical (OFIX) and Intersect ENT (XENT). View all competitors. What other stocks do shareholders of Iradimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), Paypal (PYPL), Crispr Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR). Who are Iradimed's key executives? Iradimed's management team includes the following people: Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)Mr. Christopher K. Scott, CFO & Sec. (Age 49)Mr. John McCreery, Chief Operating Officer (Age 64)Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)Mr. Louis Waldman, Controller (Age 64) What is Iradimed's stock symbol? Iradimed trades on the NASDAQ under the ticker symbol "IRMD." Who are Iradimed's major shareholders? Iradimed's stock is owned by a number of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (2.77%), RK Capital Management LLC (1.99%), Foundry Partners LLC (0.61%), Cadence Capital Management LLC (0.57%), WINTON GROUP Ltd (0.54%) and Bank of New York Mellon Corp (0.46%). Company insiders that own Iradimed stock include Anthony Vuoto, Brent Johnson, Louis S Waldman, Monty K Allen and Steven M Nardi. View institutional ownership trends for Iradimed. Which institutional investors are selling Iradimed stock? IRMD stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, AQR Capital Management LLC, Stone Ridge Asset Management LLC, and UBS Group AG. Company insiders that have sold Iradimed company stock in the last year include Anthony Vuoto, Brent Johnson, Louis S Waldman, Monty K Allen, and Steven M Nardi. View insider buying and selling activity for Iradimed. Which institutional investors are buying Iradimed stock? IRMD stock was purchased by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Assenagon Asset Management S.A., WINTON GROUP Ltd, RK Capital Management LLC, Russell Investments Group Ltd., Schonfeld Strategic Advisors LLC, Nuveen Asset Management LLC, and Bank of America Corp DE. View insider buying and selling activity for Iradimed. How do I buy shares of Iradimed? Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Iradimed's stock price today? One share of IRMD stock can currently be purchased for approximately $22.30. How big of a company is Iradimed? Iradimed has a market capitalization of $273.11 million and generates $38.52 million in revenue each year. The medical equipment provider earns $9.63 million in net income (profit) each year or $0.78 on an earnings per share basis. Iradimed employs 95 workers across the globe. What is Iradimed's official website? The official website for Iradimed is www.iradimed.com. How can I contact Iradimed? Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
